checkAd

    EQS-News  108  0 Kommentare Context Therapeutics announces bispecific antibody clinical candidate to treat CLDN6+ cancers

    EQS-News: Context Therapeutics
    Context Therapeutics announces bispecific antibody clinical candidate to treat CLDN6+ cancers

    06.12.2022 / 12:40 CET/CEST
    The issuer is solely responsible for the content of this announcement.

    0.jpgContact Details

    Proactive Investors USA

    Proactive Investors USA

    +1 347-449-0879

    na-editorial@proactiveinvestors.com


    News Source: News Direct

    06.12.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
    The issuer is solely responsible for the content of this announcement.

    The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
    Archive at www.eqs-news.com

    Language: English
    Company: Context Therapeutics
    United States
    ISIN: US21077P1084
    EQS News ID: 1506291

     
    End of News EQS News Service

    1506291  06.12.2022 CET/CEST

    fncls.ssp?fn=show_t_gif&application_id=1506291&application_name=news&site_id=wallstreet

    Lesen Sie auch




    EQS Group AG
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors


    Verfasst von EQS Group AG
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    EQS-News Context Therapeutics announces bispecific antibody clinical candidate to treat CLDN6+ cancers EQS-News: Context Therapeutics Context Therapeutics announces bispecific antibody clinical candidate to treat CLDN6+ cancers 06.12.2022 / 12:40 CET/CEST The issuer is solely responsible for the content of this announcement. Contact DetailsProactive …